Programa de Pós-Graduação em ciências da saúde da Universidade Estadual de Londrina - UEL, Londrina, PR, Brasil.
Escola de medicina, Pontifícia Universidade Católica do Paraná - PUCPR, Londrina, PR, Brasil.
Int Braz J Urol. 2022 Jul-Aug;48(4):649-659. doi: 10.1590/S1677-5538.IBJU.2021.0646.
This study examined and compared efficacy, safety, satisfaction, and complications of the retropubic Safyre™ sling and a retropubic hand-made synthetic sling (HMS) in a short-, mid- and long-term follow-up.
We retrospectively reviewed a prospectively maintained database of women who underwent Safyre™ or HMS between March 7ths 2005 and December 27ths, 2017. Patients had first assessment (7-10 days), second (40-45 days), and third (sixth month) postoperatively. Between September and December 2018, patients who completed at least one year of surgery, received a telephone call. Follow-up compared quartiles of follow-up time to determine complications (Clavien-Dindo), success rates (International Consultation on Incontinence Modular Questionnaire for Urinary Incontinence Short Form - ICIQ-UI SF), and patient satisfaction.
Three hundred fifty-one patients underwent surgery and 221 (63%) were evaluated after a median of 78.47 (± 38.69) months, 125 (55%) in the HMS, and 96 (45%) in the Safyre™ group. Higher intraoperative bladder injury was observed with Safyre™ (0% vs. 4.2%, p=0.034), and a tendency for urinary retention, requiring indwelling urinary catheter over 24 hours (2.4% vs. 8.3%, p=0.061). Both HMS (p<0.001) and Safyre™ (p<0.001) presented improvements on ICIQ-UI SF. There were no differences in satisfaction, subjective cure rates, ICIQ-UI SF, or complications between groups.
Both HMS and Safyre™ have similar satisfaction and subjective cure rates, with marked ICIQ-UI SF score improvement. Higher rates of intraoperative bladder injury were seen in patients who received Safyre™ retropubic sling.
本研究旨在对经耻骨后 Safyre™吊带和经耻骨后手制合成吊带(HMS)在短期、中期和长期随访中的疗效、安全性、满意度和并发症进行检查和比较。
我们回顾性分析了 2005 年 3 月 7 日至 2017 年 12 月 27 日期间接受 Safyre™或 HMS 的女性患者的前瞻性维护数据库。患者在术后第 7-10 天、第 40-45 天和第 6 个月进行首次评估。2018 年 9 月至 12 月,对至少完成 1 年手术的患者进行电话随访。随访比较随访时间的四分位间距,以确定并发症(Clavien-Dindo)、成功率(国际尿失禁咨询委员会尿失禁模块问卷简化版-ICIQ-UI SF)和患者满意度。
共有 351 例患者接受手术,221 例(63%)在中位数为 78.47(±38.69)个月后进行评估,其中 HMS 组 125 例(55%),Safyre™组 96 例(45%)。Safyre™组术中膀胱损伤发生率更高(0% vs. 4.2%,p=0.034),留置导尿管超过 24 小时的尿潴留发生率也有升高趋势(2.4% vs. 8.3%,p=0.061)。HMS(p<0.001)和 Safyre™(p<0.001)在 ICIQ-UI SF 上均有显著改善。两组在满意度、主观治愈率、ICIQ-UI SF 或并发症方面均无差异。
HMS 和 Safyre™ 均具有相似的满意度和主观治愈率,并且 ICIQ-UI SF 评分有显著改善。接受 Safyre™经耻骨后吊带治疗的患者术中膀胱损伤发生率更高。